187 related articles for article (PubMed ID: 36983597)
1. Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?
Chiloiro S; Giampietro A; Bianchi A; Menotti S; Angelini F; Tartaglione T; Antonini Cappellini GC; De Galitiis F; Rossi E; Schinzari G; Scoppola A; Pontecorvi A; De Marinis L; Fleseriu M
J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983597
[TBL] [Abstract][Full Text] [Related]
2. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
4. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
Malikova H; Holesta M; Fialova A; Arenbergerova M; Weichet J
Neuro Endocrinol Lett; 2018 Sep; 39(3):196-204. PubMed ID: 30431741
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.
Kotwal A; Rouleau SG; Dasari S; Kottschade L; Ryder M; Kudva YC; Markovic S; Erickson D
J Investig Med; 2022 Apr; 70(4):939-946. PubMed ID: 34969937
[TBL] [Abstract][Full Text] [Related]
6. Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review.
Menotti S; Giampietro A; Raia S; Veleno M; Angelini F; Tartaglione T; Gaudino S; Doglietto F; De Marinis L; Pontecorvi A; Bianchi A; Chiloiro S
J Pers Med; 2023 Jul; 13(8):. PubMed ID: 37623461
[TBL] [Abstract][Full Text] [Related]
7. MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.
Kurokawa R; Ota Y; Gonoi W; Hagiwara A; Kurokawa M; Mori H; Maeda E; Amemiya S; Usui Y; Sato N; Nakata Y; Moritani T; Abe O
AJNR Am J Neuroradiol; 2020 Sep; 41(9):1683-1689. PubMed ID: 32763900
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related?
Ramalho D; Araújo A; Rocha G; Duarte-Ribeiro F
Eur J Case Rep Intern Med; 2021; 8(12):003099. PubMed ID: 35059351
[TBL] [Abstract][Full Text] [Related]
9. Induction of Hypopituitarism Following Ipilimumab/Nivolumab Therapy Followed by Radiation in the Treatment of Metastatic Scalp Melanoma.
Salabei JK; Upadhyay D; Padam SA
HCA Healthc J Med; 2021; 2(5):339-343. PubMed ID: 37425126
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
[TBL] [Abstract][Full Text] [Related]
11. Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge.
Park BC; Jung S; Wright JJ; Johnson DB
Oncologist; 2022 Dec; 27(12):e967-e969. PubMed ID: 36288471
[TBL] [Abstract][Full Text] [Related]
12. A COMMON PITUITARY AUTOANTIBODY IN TWO PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-MEDIATED HYPOPHYSITIS: ZCCHC8.
Leiter A; Gnjatic S; Fowkes M; Kim-Schulze S; Laface I; Galsky MD; Gallagher EJ
AACE Clin Case Rep; 2020; 6(4):e151-e160. PubMed ID: 32671216
[TBL] [Abstract][Full Text] [Related]
13. Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature.
Newman C; Kgosidalwa O; Hakami OA; Kennedy C; Grogan L; Agha A
BMC Endocr Disord; 2021 Feb; 21(1):33. PubMed ID: 33639911
[TBL] [Abstract][Full Text] [Related]
14. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
15. An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Prospective Single-Center Experience.
Chiloiro S; Tartaglione T; Angelini F; Bianchi A; Arena V; Giampietro A; Mormando M; Sciandra M; Laino ME; De Marinis L
Neuroendocrinology; 2017; 104(3):280-290. PubMed ID: 27165294
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis.
Chodakiewitz Y; Brown S; Boxerman JL; Brody JM; Rogg JM
Clin Neurol Neurosurg; 2014 Oct; 125():125-30. PubMed ID: 25127260
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Nada A; Bhat R; Cousins J
Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
[TBL] [Abstract][Full Text] [Related]
18. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
20. Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series.
Atkins P; Ur E
Endocr Res; 2020 Nov; 45(4):246-253. PubMed ID: 32892666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
